Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver
mi
from
Aurora, CO
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Yale New Haven Hospital
mi
from
North Haven, CT
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Yale New Haven Hospital
mi
from
North Haven, CT
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Miami Miller School of Medicine
mi
from
Miami, FL
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center-Duchossois Center for Advanced Medicine (DCAM)
mi
from
Chicago, IL
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center-Duchossois Center for Advanced Medicine (DCAM)
mi
from
Chicago, IL
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Medicine Neurology & Neurosurgery
mi
from
Baltimore, MD
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Medicine Neurology & Neurosurgery
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Harvard Medical School/Brigham & Women's Hospital
mi
from
Boston, MA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Harvard Medical School/Brigham & Women's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Wayne State University
mi
from
Detroit, MI
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Holy Name Hospital
mi
from
Teaneck, NJ
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Holy Name Hospital
mi
from
Teaneck, NJ
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
The University of New Mexico - Multiple Sclerosis Specialty Clinic
mi
from
Albuquerque, NM
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
The University of New Mexico - Multiple Sclerosis Specialty Clinic
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
SUNY Buffalo - University Neurology, Inc
mi
from
Buffalo, NY
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
SUNY Buffalo - University Neurology, Inc
mi
from
Buffalo, NY
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Mount Sinai School of Medicine - Corinne Goldsmith Dickinson Center for MS
mi
from
New York, NY
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Mount Sinai School of Medicine - Corinne Goldsmith Dickinson Center for MS
mi
from
New York, NY
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
State University of New York (SUNY)
mi
from
Stony Brook, NY
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
State University of New York (SUNY)
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Raleigh Neurology Associates
mi
from
Raleigh, NC
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Raleigh Neurology Associates
mi
from
Raleigh, NC
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Providence Multiple Sclerosis Center
mi
from
Portland, OR
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Providence Multiple Sclerosis Center
mi
from
Portland, OR
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Cole Neuroscience Center
mi
from
Knoxville, TN
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Cole Neuroscience Center
mi
from
Knoxville, TN
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Vanderbilt Comprehensive Multiple Sclerosis Center
mi
from
Nashville, TN
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Vanderbilt Comprehensive Multiple Sclerosis Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Central Texas Neurology Consultants, P.A.
mi
from
Round Rock, TX
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Central Texas Neurology Consultants, P.A.
mi
from
Round Rock, TX
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Virginia Mason Medical Center
mi
from
Seattle, WA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Nova Clinical Research, Llc
mi
from
Bradenton, FL
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Nova Clinical Research, Llc
mi
from
Bradenton, FL
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Neuro-Pain Medical Center
mi
from
Fresno, CA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Neuro-Pain Medical Center
mi
from
Fresno, CA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University South Florida Medical Clinic
mi
from
Tampa, FL
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University South Florida Medical Clinic
mi
from
Tampa, FL
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Rowe Neurology Institute
mi
from
Lenexa, KA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Rowe Neurology Institute
mi
from
Lenexa, KA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Minneapolis Clinic of Neurology, Ltd.
mi
from
Minneapolis, MN
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Minneapolis Clinic of Neurology, Ltd.
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Mellen Center for MS
mi
from
Cleveland, OH
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Mellen Center for MS
mi
from
Cleveland, OH
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Ochsner Health System
mi
from
New Orleans, LA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Ochsner Health System
mi
from
New Orleans, LA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Austin Hospital
mi
from
Heidelberg,
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Austin Hospital
mi
from
Heidelberg,
Click here to add this to my saved trials
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cleveland, OH
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Ann Arbor, MI
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Francisco, CA
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
mi
from
Buenos Aires,
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
mi
from
Buenos Aires,
Click here to add this to my saved trials
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Washington,
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
PALISADE Follow-on Study (ARC004)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Status: Enrolling
Updated:  12/31/1969
Arkansas Children's Hospital
mi
from
Little Rock, AR
PALISADE Follow-on Study (ARC004)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Status: Enrolling
Updated: 12/31/1969
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
PALISADE Follow-on Study (ARC004)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Status: Enrolling
Updated:  12/31/1969
Allergy and Asthma Associates of Southern California
mi
from
Mission Viejo, CA
PALISADE Follow-on Study (ARC004)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Status: Enrolling
Updated: 12/31/1969
Allergy and Asthma Associates of Southern California
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
PALISADE Follow-on Study (ARC004)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Status: Enrolling
Updated:  12/31/1969
Sean N. Parker Center for Allergy Research at Stanford University Packard-El Camino Hospital
mi
from
Mountain View, CA
PALISADE Follow-on Study (ARC004)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Status: Enrolling
Updated: 12/31/1969
Sean N. Parker Center for Allergy Research at Stanford University Packard-El Camino Hospital
mi
from
Mountain View, CA
Click here to add this to my saved trials
PALISADE Follow-on Study (ARC004)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Status: Enrolling
Updated:  12/31/1969
Allergy & Asthma Medical Group & Research Center A.P.C.
mi
from
San Diego, CA
PALISADE Follow-on Study (ARC004)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Status: Enrolling
Updated: 12/31/1969
Allergy & Asthma Medical Group & Research Center A.P.C.
mi
from
San Diego, CA
Click here to add this to my saved trials
PALISADE Follow-on Study (ARC004)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Status: Enrolling
Updated:  12/31/1969
Colorado Allergy & Asthma Centers, PC
mi
from
Centennial, CO
PALISADE Follow-on Study (ARC004)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Status: Enrolling
Updated: 12/31/1969
Colorado Allergy & Asthma Centers, PC
mi
from
Centennial, CO
Click here to add this to my saved trials
PALISADE Follow-on Study (ARC004)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Status: Enrolling
Updated:  12/31/1969
Windom Allergy, Asthma and Sinus
mi
from
Sarasota, FL
PALISADE Follow-on Study (ARC004)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Status: Enrolling
Updated: 12/31/1969
Windom Allergy, Asthma and Sinus
mi
from
Sarasota, FL
Click here to add this to my saved trials
PALISADE Follow-on Study (ARC004)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Status: Enrolling
Updated:  12/31/1969
Atlanta Allergy & Asthma Clinic, PA
mi
from
Marietta, GA
PALISADE Follow-on Study (ARC004)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Status: Enrolling
Updated: 12/31/1969
Atlanta Allergy & Asthma Clinic, PA
mi
from
Marietta, GA
Click here to add this to my saved trials
PALISADE Follow-on Study (ARC004)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Status: Enrolling
Updated:  12/31/1969
Riley Hospital for Children, IU Health North Hospital
mi
from
Carmel, IN
PALISADE Follow-on Study (ARC004)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Status: Enrolling
Updated: 12/31/1969
Riley Hospital for Children, IU Health North Hospital
mi
from
Carmel, IN
Click here to add this to my saved trials